



AYURCANN

Ayurcann Holdings Corp.

Condensed Interim Consolidated Financial Statements,

For the Nine Months Ended March 31, 2024

(Expressed in Canadian Dollars)

(Unaudited)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

These unaudited condensed interim consolidated financial statements, including comparatives, have been prepared in accordance with International Accounting Standards (“IAS”) 34 ‘Interim Financial Reporting’ (“IAS 34”) using accounting policies consistent with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”) and Interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”).

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor. The accompanying unaudited condensed interim consolidated financial statements of Ayurcann Holdings Corp. (“Company”) have been prepared by and are the responsibility of the Company’s management. The unaudited condensed interim consolidated financial statements are prepared in accordance with accounting principles generally accepted in Canada (these statements are prepared under International Financial Reporting Standards (IFRS)) and reflect management’s best estimates and judgment based on information currently available. The Company’s independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity’s auditor.

Ayurcann Holdings Corp.
Condensed Interim Consolidated Statements of Financial Position
As at March 31, 2024 and June 30, 2023
(Unaudited - Expressed in Canadian dollars)

<i>As at</i>	Note	31/Mar/24	30/Jun/23
ASSETS			
Cash		\$ 3,831,235	\$ 971,959
Trade and other receivables	5	5,044,345	4,840,471
Prepaid expenses and deposits		98,657	164,013
Income tax receivable		21,146	21,146
Inventories	6	6,140,807	3,277,081
Current Assets		15,136,190	9,274,669
Property and equipment	7	1,019,550	1,016,415
Right-of-use assets	8	192,886	135,339
Intangible assets	4, 9	1,891,473	2,303,973
Non-Current Assets		3,103,908	3,455,726
Total Assets		18,240,098	12,730,395
LIABILITIES			
Trade and other payables	10	\$ 14,209,080	\$ 9,426,041
Harmonized sales tax payable		179,429	30,943
Current portion of lease liability	8	67,656	124,122
Due to related parties	12	400,000	400,000
Current Liabilities		14,856,165	9,981,106
Lease liability	8	161,284	56,774
Other LT Liabilities		138,137	-
Non-Current Liabilities		299,420	56,774
Total Liabilities		15,155,585	10,037,880
SHAREHOLDERS' EQUITY			
Common share capital	13b	\$ 12,849,769	\$ 11,155,019
Warrant reserve	13c	935,744	935,744
Stock based payments	13d	1,013,042	1,013,042
Accumulated deficit		(11,714,043)	(10,411,290)
Total Shareholders' Equity		3,084,513	2,692,516
Total Liabilities and Shareholders' Equity		18,240,098	12,730,395
Nature of operations and going concern	1		
Subsequent events	16		

Approved on behalf of the Board of Directors:

/s/ Igal Sudman Director

/s/ Roman Buzaker Director

The accompanying notes are an integral part of the condensed interim consolidated financial statements.

Ayurcann Holdings Corp.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

For the three and nine months ended March 31, 2024 and 2023

(Unaudited - Expressed in Canadian dollars)

	Note	Three months ended March 31,		Nine months ended March 31,	
		2024	2023	2024	2023
Revenues					
Product Sales (B2C)		\$ 11,323,369	\$ 5,537,378	\$ 33,753,763	\$ 12,613,680
Product Sales (B2B)		331,991	128,266	420,751	544,720
Services		-	227,707	12,010	502,161
Gross Revenues		11,655,360	5,893,351	34,186,524	13,660,562
Agency and Service Fees		(84,920)	(17,768)	(321,351)	(17,768)
Excise Duties		(5,083,282)	(3,022,718)	(15,087,791)	(5,648,931)
Net Revenue		6,487,158	2,852,865	18,777,381	7,993,862
Cost of Goods Sold		(4,067,916)	(2,013,472)	(11,926,875)	(5,426,738)
Gross Margin		2,419,242	839,393	6,850,506	2,567,124
Salaries and Wages		570,781	418,194	1,548,951	1,164,426
Office and General		525,585	244,755	1,490,760	1,058,127
Sales and Marketing		1,239,130	894,682	3,226,946	1,540,025
Professional Fees		99,804	188,129	502,340	514,309
Depreciation of Property and Equipment	7	40,349	2,716	145,872	4,479
Amortization of Intangible Assets	4, 9	137,500	135,616	412,500	308,904
Share Based Payments	13b	111,250	-	471,734	116,503
Expenses		2,724,400	1,884,093	7,799,103	4,706,773
Operating Income/(Loss)		(305,158)	(1,044,699)	(948,597)	(2,139,649)
Finance Costs		44,214	5,986	352,360	9,117
Other Income		209	-	1,796	-
Net Loss and Comprehensive Loss		\$ (349,581)	\$ (1,050,686)	\$ (1,302,753)	\$ (2,148,766)
Weighted Average Shares Outstanding					
- Basic and Diluted		192,786,006	157,028,030	171,671,099	147,313,355
Basic and Diluted Loss per Share		\$ (0.002)	\$ (0.007)	\$ (0.008)	\$ (0.015)

* All share and per share numbers have been adjusted to reflect the share exchange ratio as if it had occurred at the beginning of all reported periods.

Ayurcann Holdings Corp.

Condensed Interim Consolidated Statements of Cash Flows

For the nine months ended March 31, 2024 and 2023

(Unaudited - Expressed in Canadian dollars)

	Note	Nine months ended March 31,	
		2024	2023
OPERATING ACTIVITIES			
Net Income (Loss) for the period		\$ (1,302,753)	\$ (2,148,766)
Items Not Affecting Cash			
Depreciation of property and equipment		391,958	153,027
Amortization of intangible assets	4, 9	412,500	308,904
Amortization of right-of-use assets	8	114,637	64,637
Share based payments	13b	1,694,750	284,003
Amortization of deferred lease inducement	8	979	(489)
Change in Non-Cash Working Capital Items			
Trade and other receivables		(203,875)	(754,376)
Intercompany Receivables		119,706	-
Prepaid expenses		65,356	(14,380)
Harmonized sales tax payable		148,486	(55,682)
Inventories		(2,863,726)	(184,906)
Trade and other payables		4,724,504	2,628,326
Income tax		-	121,063
Cash Flows Provided (Used) for Operating Activities		3,302,522	401,361
INVESTING ACTIVITIES			
Property and equipment additions		(395,093)	(169,465)
ROU additions		(172,184)	20,406
Cash flows used in Investing activities		(567,277)	(149,059)
FINANCING ACTIVITIES			
Finance lease payments	8	105,600	(144,016)
Repayment of long term debt		138,137	-
Share repurchase	13b	-	(20,472)
Cash Flows Used in Financing Activities		124,031	(164,488)
(Decrease)/increase in cash		2,859,276	87,814
Cash, beginning of period		971,959	1,354,816
Cash, end of period		3,831,235	1,442,630
Non-cash transactions			
Shares issued for services and financing settlement		\$ 1,694,750	\$ 284,003

The accompanying notes are an integral part of the consolidated financial statements.

Ayurcann Holdings Corp.**Condensed Interim Consolidated Statements of Changes in Equity**

For the nine months ended March 31, 2024 and 2023

(Unaudited - Expressed in Canadian dollars)

	Note	Common shares		Reserves		Accumulated deficit	Total
		No. of shares	Dollar Amount	Warrants	Stock based payments		
As at July 1, 2022		121,099,318	8,049,363	935,744	1,013,042	(5,104,163)	4,893,986
RSUs converted for common shares		1,226,350	116,503	0	0	0	116,503
Share buyback		(467,000)	(20,339)	0	0	0	(20,339)
Share based payments		3,002,254	167,367	0	0	0	167,367
Common shares issued on acquisition		32,352,941	2,750,000	0	0	0	2,750,000
Net loss and comprehensive loss for the period		0	0	0	0	(2,148,766)	(2,148,766)
As at March 31, 2023		157,213,863	11,062,894	935,744	1,013,042	(7,252,929)	5,758,751
Share based payments		1,675,000	92,125	0	0	0	92,125
Net loss and comprehensive loss for the period		0	0	0	0	(3,158,360)	(3,158,360)
As at June 30, 2023		158,888,863	11,155,019	935,744	1,013,042	(10,411,290)	2,692,516
Share based payments		35,815,000	1,694,750	0	0	0	1,694,750
Net loss and comprehensive loss for the period		0	0	0	0	(1,302,753)	(1,302,753)
As at March 31, 2024		194,703,863	12,849,769	935,744	1,013,042	(11,714,043)	3,084,513

The accompanying notes are an integral part of the financial statements.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

1. Nature of Operations and Going Concern

Ayurcann Inc. was incorporated under the Canada Business Corporations Act (“CBCA”) on June 22, 2018. Pacific Coal Corp. (“Company”) was incorporated on August 26, 2010, under the Business Corporation Act (Ontario). On April 12, 2011, the Company changed its name to Canada Coal Inc.

On March 26, 2021, the Company was renamed to Ayurcann Holdings Corp., following the reverse takeover transaction (RTO) with Ayurcann Inc., which became a wholly owned subsidiary of Ayurcann Holdings Corp. Pursuant to RTO accounting standards, these consolidated financial statements reflect the continuation of the financial position, operating results and cash flows of the Company’s legal subsidiary, Ayurcann Inc. The Company’s principal business activity consists of providing post-harvest outsourcing solutions to licensed cannabis producers.

On April 8, 2021, the Company commenced trading on the Canadian Securities Exchange under the symbol “AYUR.” On November 30, 2021, the Company began trading on the OTC Markets Group Inc. (OTCQB) under the symbol “CDCLF”. On January 22, 2022, the Company received approval from OTC Markets Group Inc., to change its symbol to "AYURF". On August 19, 2021, the Company inter-listed on the Frankfurt Stock Exchange under the symbol “3ZQ0.” The Company’s registered head office is 1080 Brock Road, Unit 6, Pickering, L1W3X4. The Company’s website is <https://ayurcann.com/>.

On April 20, 2022, the Company announced that it received a flower sales license from Health Canada, which will allow the Company to sell dried cannabis flower products in Canada through authorized distributors and retailers.

These consolidated financial statements have been prepared based on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations.

The Company incurred a net loss and comprehensive loss of \$1,302,753 during nine months ended March 31, 2024. The Company’s accumulated deficit was \$11,714,043. A large portion of the accumulated deficit is related to the one-time transaction costs as a result of the reverse-takeover transaction. At March 31, 2024, the Company had working capital of \$280,025.

The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing and or achieve profitable operations in the future. Management is aware, in making its assessment, of material uncertainties related to events or conditions that cast significant doubt upon the Company’s ability to continue as a going concern. Management is actively pursuing funding options required to meet the Company’s requirements on an ongoing basis. There is no assurance that sources of funds will be available or obtained on favorable terms or obtained at all. Historically, the Company has obtained funding from the issuance of common shares, proceeds from the exercise of share purchase warrants, and short-and long-term debt issuances, however, there can be no assurances that the Company will be achieve this.

These consolidated financial statements do not reflect the adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis was not appropriate for these consolidated financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported revenues and expenses, and the consolidated statements of financial position classifications used. Such adjustments could be material.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

2. Basis of Preparation

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC").

The policies applied in these condensed audited consolidated financial statements are based on IFRSs issued and outstanding as of May 24, 2024, the date the Board of Directors approved the statements.

Basis of measurement

These condensed audited consolidated financial statements have been prepared on an accrual basis and are based on historical costs, except for certain financial instruments, which are measured at fair value, as explained in the accounting policies set out in Note 3.

Functional and presentation currency

The financial statements are presented in Canadian dollars, the Company's functional currency.

3. Significant Accounting Policies

Significant accounting estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make significant judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and related footnote disclosures. Use of available information and the application of judgment are inherent in the formation of estimates. Actual results in the future can differ from these estimates, which may be material to future financial statements.

Significant estimates and underlying assumptions are reviewed on a periodic basis. Management uses historical experience and various other factors it believes to be reasonable under the circumstances as the basis for its judgments and estimates. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements, are outlined below:

- Recovery of accounts receivable - the Company estimates the collectability and timing of collection of its receivables, classifying them as current assets or long-term assets, and applies provisions for collectability when necessary.
- Valuation of inventory – the provision for obsolescence and the estimated net realizable value.
- Convertible promissory note is separated into its liability and equity components using the effective interest rate method. The fair value of the liability component at the time of issue is calculated as the discounted cash flows for the convertible debenture using the effective interest rate which was the estimated rate for a promissory note without a conversion feature. The fair value of the equity component was determined at the time of issue as the difference between the face value of the convertible promissory note and the fair value of the liability component. Changes in the input assumptions can materially affect the fair value estimates and the Company's classification between debt and equity components.
- Property and equipment and right-of-use assets - management is required to estimate the useful lives and residual value of property and equipment and right-of-use assets which are included in the statements of financial position and the related depreciation included in the statements of loss.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

- Share-based payments – management is required to make a number of estimates when determining the compensation expense resulting from share-based transactions, including the forfeiture rate and expected life of the instruments.
- Estimated useful lives, amortization of intangible assets, and impairment testing – amortization of intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any. The assessment of any impairment is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and useful lives of assets.
- Business Combinations – classification of an acquisition as a business combination or an asset acquisition depends on whether the assets acquired constitute a business, which can be complex judgement. Whether an acquisition is classified as a business combination or asset acquisition can have a significant impact on the entries made on and after acquisition. In determining the fair value of all identifiable assets and liabilities acquired, the most significant estimates relate to intangible assets. For any intangible asset identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. The evaluations are linked closely to the assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied.
- Recoverability of deferred income tax assets – assessing whether the realization of tax losses against future taxable income for income tax purposes is probable.
- Impairment of property, plant and equipment and right-of-use assets - assessing whether indicators of impairment exist at reporting period ends and, if required, determining recoverable amounts including assumptions and inputs thereto; and
- Going concern assumption – Going concern presentation of the financial statements which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due.

Revenue recognition

The Company earns revenue from the extraction and processing of cannabis oil-based products - both through processing its own biomass cannabis and providing same services to its customers. The Company offers its product lines, both B2B and B2C.

Gross revenue includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue from sale of goods, as presented in the consolidated statements of loss and comprehensive loss, represents revenue from the sale of goods less applicable excise taxes, expected price discounts, and allowances for customer returns. Excise taxes are a production tax which is payable when a cannabis product is delivered to the customer and are not directly related to the value of revenue.

Revenue is measured at the fair value of the consideration received or receivable, net of estimated returns and discounts. The Company considers the terms of the sales contracts as well as industry practices, taking into consideration the type of customer, the nature of the transaction and the specific circumstances of each arrangement.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

The Company accounts for revenue from a contract with a customer only when the following criteria are met:

- the contract has been approved by the parties to the contract.
- each party's rights in relation to the goods or services to be transferred can be identified.
- the payment terms for the goods or services to be transferred can be identified.
- the contract has commercial substance; and
- it is probable that the consideration to which the entity is entitled to in exchange for the goods or services will be collected.

Revenue from product sales and the related cost of goods sold are recognized on delivery of goods to the customer. Processing fee revenue is recognized on completion of services. For contracts that permit the customer to return a product, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, at the point of sale, the amount of revenue recognized is adjusted for expected returns, which are estimated based on the historical experience and knowledge of the customer and market expectations. At the same time, the Company would also have a right to recover returned goods, so consequently a refund liability and a right to recover returned goods assets are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the assets and liability accordingly.

Cash & Cash Equivalents

Cash and cash equivalents comprise cash at banks and on hand, and short-term deposits with an original maturity of three months or less or cashable without penalty which are readily convertible into a known amount of cash.

Property and equipment

Property and equipment are recorded at cost, net of accumulated depreciation, and impairment charges, if any. Depreciation is provided for over the assets' useful lives at the following annual rates and methods:

Furniture and fixtures	Declining balance method	20%
Leasehold improvements	Straight-line method	Lease term
Machinery and equipment	Declining balance method	20%
Computer	Declining balance method	55%
Signs	Declining balance method	20%

Impairment of non-current assets

Property and equipment are assessed for indications of impairment at the end of each reporting period. If such indications exist, then the recoverable amount of the asset is estimated.

An impairment loss is recognized when the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of an asset is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and risks specific to the asset. Impairment losses are recognized in operations for the year in which they are identified.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

Intangible assets

Intangible assets are stated at cost, net of accumulated amortization and accumulated impairment losses, if any.

The Company amortizes on a straight-line basis the intangible assets over the assets useful lives which is determined to be 5 years.

Current income tax

Current income tax expense represents the sum of income tax currently payable. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the date of the statement of financial position.

Deferred income tax

Deferred income tax is provided using the asset and liability method on temporary differences at the date of the statement of financial position between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred income tax assets are recognized for all deductible temporary differences, and the carry forward of unused tax losses, to the extent that it is probable that taxable Income will be available against which the deductible temporary differences and the carry forward of unused tax losses can be utilized.

The carrying amount of deferred income tax assets is reviewed at each date of the statement of financial position and reduced to the extent that it is no longer probable that sufficient taxable income will be available to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are reassessed at each date of the statement of financial position and are recognized to the extent that it has become probable that future taxable income will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the date of the statement of financial position.

Deferred income tax relating to items recognized directly in equity is recognized in equity and not in the statement of income and comprehensive (loss) income.

Deferred income tax assets and deferred income tax liabilities are offset if, and only if, a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered.

Foreign currency transactions

Monetary assets and liabilities denominated in foreign currencies are translated into Canadian dollars at the closing exchange rate being the rate prevailing on the statement of financial position date. Non-monetary assets and liabilities are translated at historical rates of exchange at the time of the acquisition of assets or obligations incurred. Revenues and expenses are translated at the rate of exchange in effect at the date of the transactions. Foreign exchange translation gains and losses are recorded in operations in the period in which they occur.

Financial instruments

Recognition

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

The Company recognizes a financial asset or financial liability on the statement of financial position when it becomes party to the contractual provisions of the financial instrument. Financial assets are initially measured at fair value and are derecognized either when the Company has transferred substantially all the risks and rewards of ownership of the financial asset, or when cash flows expire. Financial liabilities are initially measured at fair value and are derecognized when the obligation specified in the contract is discharged, cancelled, or expired.

A write-off of a financial asset (or a portion thereof) constitutes a derecognition event. Write-off occurs when the Company has no reasonable expectations of recovering the contractual cash flows on a financial asset.

Classification and measurement

The Company determines the classification of its financial instruments at initial recognition. Financial assets and financial liabilities are classified according to the following measurement categories:

- those to be measured subsequently at fair value, either through profit or loss (“FVTPL”) or through other comprehensive income (“FVTOCI”); and
- those to be measured subsequently at amortized cost.

The classification and measurement of financial assets after initial recognition at fair value depends on the business model for managing the financial asset and the contractual terms of the cash flows. Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding, are generally measured at amortized cost at each subsequent reporting period. All other financial assets are measured at their fair values at each subsequent reporting period, with any changes recorded through profit or loss or through other comprehensive income (which designation is made as an irrevocable election at the time of recognition). After initial recognition at fair value, financial liabilities are classified and measured at either:

- amortized cost.
- FVTPL, if the Company has made an irrevocable election at the time of recognition, or when required (for items such as instruments held for trading or derivatives); or
- FVTOCI, when the change in fair value is attributable to changes in the Company’s credit risk.

The Company reclassifies financial assets when and only when its business model for managing those assets changes. Financial liabilities are not reclassified.

Transaction costs that are directly attributable to the acquisition or issuance of a financial asset or financial liability classified as subsequently measured at amortized cost are included in the fair value of the instrument on initial recognition. Transaction costs for financial assets and financial liabilities classified at fair value through profit or loss are expensed in profit or loss.

Fair value of financial instruments

The determination of the fair value of financial assets and liabilities, for which there is no observable market price, requires the use of valuation techniques. For financial instruments that trade infrequently and have little price transparency, fair value is less objective as such it requires varying degrees of judgment. The use of judgment in valuing financial instruments includes assessing qualitative factors such as liquidity, concentration, uncertainty of market factors, pricing assumptions and other risks affecting the particular instrument.

The Company measures fair values using the following fair value hierarchy that reflects the significance of the inputs used in making the measurements:

Level 1: Quoted market price in an active market for an identical instrument.

Level 2: Valuation techniques based on observable inputs derived either directly or indirectly from market prices. This category includes instruments valued using quoted market prices in active markets for similar instruments, quoted market prices for identical or similar instruments in markets that are considered less than active or other valuation

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

techniques where all significant inputs are directly or indirectly observable from market data.

Level 3: Valuation techniques using significant unobservable inputs. This category includes all instruments where the valuation technique includes inputs not based on observable data and the unobservable inputs have a significant effect on the instrument's valuation. This category includes instruments that are valued based on quoted market prices for similar instruments where significant unobservable adjustments or assumptions are required to reflect differences between the instruments.

As of March 31, 2024, except for cash, none of the Company's financial instruments are recorded at fair value in the statements of financial position. Cash is classified as Level 1.

Compound Instruments

The components of compound instruments (convertible promissory note) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash of another financial asset for a fixed number of the Company's own equity instruments is an equity instrument.

At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion or at the instrument's maturity date.

The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option.

Transaction costs that relate to the issue of the convertible debenture are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the term of the convertible debentures using the effective interest method.

Impairment of financial assets

The expected credit loss ("ECL") impairment model applies to financial assets measured at amortized cost, contract assets and debt investments at FVOCI, but not to investments in equity instruments. Allowances for ECL are recognized on all financial assets that are classified either at amortized cost or FVOCI and for all loan commitments and financial guarantees that are not measured at FVTPL. Allowances represent credit losses that reflect an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes, the time value of money and reasonable and supportable information about past events, current conditions and forecasts of future economic conditions.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

ECL allowances are measured at amounts equal to either (i) 12-month ECL (also referred to as Stage 1 ECL), which comprises an allowance for all non-impaired financial instruments that have not experienced a significant increase in credit risk ("SICR") since initial recognition; or (ii) lifetime ECL (also referred to as Stage 2 ECL), which comprises an allowance for those financial instruments that have experienced a SICR since initial recognition; or where there is objective evidence of impairment (Stage 3 ECL). Lifetime ECL is recognized for Stage 2 and 3 financial instruments compared to 12-month ECL for Stage 1 financial instruments.

Inventories

Inventories consist of finished goods, work-in-process and raw materials and are valued at the lower of cost and net realizable value. Cost is determined using the standard cost method, which is updated regularly to reflect current conditions and approximate cost based on the weighted average formula. Cost of inventories includes cost of purchase (purchase price, transport, handling, and other costs directly attributable to the acquisition of inventories), cost of conversion, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

All inventories are reviewed for impairment due to slow moving and obsolete inventory. The provision for obsolete, slow moving and defective inventories are recognized in profit or loss. Previous write downs to net realizable value are reversed to the extent there is a subsequent increase in the net realizable value of the inventory.

Related party transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Related parties, which may be individuals or corporate entities, are also considered to be related if they are subject to common control or common significant influence. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. Related party transactions that are in the normal course of business and have commercial substance are measured at the exchange amount.

Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) that has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risk specific to the obligation. The increase in the provision due to the passage of time is recognized as an interest expense.

Comprehensive loss per share

The basic comprehensive income (loss) per share is computed by dividing comprehensive income (loss) by the weighted average number of common shares outstanding during the current period. The diluted comprehensive income (loss) per share reflects the potential dilution of common share equivalents, such as outstanding stock options and share purchase warrants, in the weighted average number of common shares outstanding during the period, if dilutive. The "treasury stock method" is used for the assumed proceeds upon the exercise of the options and warrants that are used to purchase common shares at the average market price during the period.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

Equity-based payments

Equity-based share-based payment transactions with parties other than employees are measured at the fair value of goods or services received, except where that fair value cannot be estimated reliably, in which case they are measured at the fair value of the equity instruments granted, measured at the date the entity obtains the goods or the counterparty renders the service.

The fair value of stock options, warrants, and restricted share units (“RSU’s”) granted is measured using the Black-Scholes option-pricing model, considering the terms and conditions upon which the instruments were granted.

Repurchase of Shares

Repurchase of shares is recorded using the constructive retirement method which is used under the assumption that the repurchased shares will not be reissued in the future. Under this approach, the amount by which the repurchased amount was less than the stated capital of the shares, if any, is credited to contributed surplus. The stated capital of the repurchased shares is determined based on the original cost of the particular shares at the time of the repurchase.

Government grants and assistance

Grants and subsidies are recognized at their fair value where there is reasonable assurance that the grant will be received, and the Company will comply with all the attached conditions. Fair value signifies the amount received in cash. The grants and subsidies are presented as ‘other fees in operations.

Leases (“IFRS 16”)

IFRS 16 introduced a single, on-balance sheet accounting model for leases. The Company, as a lessee, has recognized right-of use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments.

A right-of-use asset is initially measured at cost, and subsequently at cost less any accumulated depreciation or impairment losses and adjusted for certain re-measurements of the lease liability. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. The Company primarily uses its incremental borrowing rate as the discount rate.

The lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payments made. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised.

The Company has furthermore applied judgment to determine the applicable discount rate. The discount rate is based on the Company's incremental borrowing rate and reflects the current market assessments of the time value of money and the associated risks for which the estimates of future cash flows have not been adjusted for.

Basis of consolidation

These consolidated financial statements incorporate the financial statements of the Company and its subsidiary. The subsidiary is consolidated from the date of acquisition, being the date on which the Company obtains control, and continues to be consolidated until the date that such control ceases. Control is achieved when an investor has power over an investee to direct its activities, exposure to variable returns from an investee, and the ability to use the power to affect the investor's returns.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

The results of subsidiaries acquired or disposed of during the period presented are included in the consolidated statements of comprehensive loss from the effective date of control and up to the effective date of disposal or loss of control, as appropriate. All intercompany transactions, balances, income and expenses are eliminated upon consolidation.

3. Capital Management

The Company defines capital as total shareholders' equity. The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the growth and development of its operations and bring new products to market and to ensure it continues as a going concern. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company will continue to assess new opportunities and seek to acquire an interest in growth situations if it feels there is sufficient economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the period ending March 31, 2024. The Company is not subject to externally imposed capital requirements.

4. Acquisition

Joints and Hustle & Shake Inc.

On September 7, 2022, the Company completed the acquisition of Joints and Hustle & Shake Inc. by issuing 32,352,941 common shares of the Company in exchange for 100% of issued and outstanding shares of Joints and Hustle & Shake Inc. Accordingly, Joints and Hustle & Shake Inc. ("Joints and Hustle") is now a wholly owned subsidiary of the Company. The consideration shares are subject to a statutory hold period of four months and one day and, pursuant to the terms of the Share Purchase Agreement, (i) have been deposited into escrow and are to be released every six months in 25% allotments; and (ii) are subject to post-closing downward adjustments pursuant to the terms and conditions of the escrow agreement.

Since Joints and Hustle did not meet the definition of a business under IFRS 3 – Business Combinations, the acquisition was accounted for as a purchase of Joints and Hustle assets. The consideration paid was determined as equity-settled share-based payments under IFRS 2, at the fair value of the equity of the Company issued to the shareholders of Joints and Hustle on the date of closing as noted above. IFRS 2 requires the shares issued for the acquisition of the net assets of Joints and Hustle to be measured at the fair value of the net assets, unless the fair value cannot be reliably estimated.

The following represents the preliminary fair value allocation to identifiable net assets acquired at March 31, 2023. Remeasurement may be made up to the finalization of the purchase price allocation which cannot be later than September 7, 2023 (one year after the transaction per IFRS 3.45):

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

	Total
Intangible assets (brand)	\$ 2,750,000
	<u>2,750,000</u>
Fair value of consideration paid:	
Common shares	2,750,000
	<u>\$ 2,750,000</u>

The Company plans to amortize its intangible assets over its useful life of 5 years. The Company recorded an amortization expense of \$412,500 for the nine months ended March 31, 2024, and \$858,527 since inception.

5. Trade and Other Receivables

Trade and other receivables are collectible from customer sales. The following is an aging analysis of the Company's trade and other receivables:

	Current	31 to 60	61 to 90	91+	Total
Balance Outstanding, July 1, 2022	\$ 1,363,440	\$ 36,476	\$ -	\$ -	\$ 1,399,916
Change	3,404,038	157,518	96,247	135,272	3,793,075
Balance Outstanding, June 30, 2023	4,767,478	193,994	96,247	135,272	5,192,991
Change	(657,198)	495,749	72,489	292,835	203,875
Balance Outstanding, March 31, 2024	\$ 4,110,280	\$ 689,743	\$ 168,736	\$ 428,106	\$ 5,396,865

As of March 31, 2024, the Company recorded a bad debt expense of \$nil. (\$nil as at March 31, 2023). As at June 30, 2023 the Company had a bad debt expense of \$352,520 due to CCAA protection of one of the customers. The company held no collateral for any receivable amounts outstanding as at June 30, 2023.

6. Inventories

	31/Mar/24	30/Jun/23
Work in Process	\$ 249,283	\$ 283,137
Finished Goods	275,556	215,014
Bulk	1,015,474	793,345
Facility Related/Other	239,741	120,016
Packaging materials, cartridges and other:	2,244,492	971,298
Packaged goods	141,487	230,594
Subcontractor and Labour Inventory	974,877	-
Biomass	999,896	558,206
Inventory in transit	2	105,471
Total Inventory	\$ 6,140,807	\$ 3,277,081

Write-downs to net realizable value for obsolete and slow-moving inventories of \$nil during the period ending March 31, 2024 (\$nil during the period ending June 30, 2023) were included in cost of goods sold for the period. Inventories recognized as an expense in the period ending March 31, 2024 and June 30, 2023 are recorded in the cost of goods sold presented in the statements of comprehensive loss.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

7. Property and Equipment

	Furniture and Fixtures	Leasehold Improvements	Machinery and Equipment	Computer	Signs	Total
Cost						
As at July 1, 2022	\$ 23,330	\$ 993,146	\$ 407,730	\$ 30,300	\$ 825	\$1,455,330
Additions	-	6,497	159,969	2,999	-	169,465
As at March 31, 2023	23,330	999,643	567,699	33,299	825	1,624,796
Additions	-	2,290	125,003	646	-	127,940
As at June 30, 2023	23,330	1,001,933	692,702	33,946	825	1,752,735
Additions	4,508	19,056	155,193	3,543	-	395,093
As at March 31, 2024	\$ 27,837	\$ 1,020,989	\$ 847,895	\$ 37,488	\$ 825	\$2,147,828
Accumulated Depreciation						
As at June 30, 2022	\$ 6,716	\$ 391,380	\$ 93,097	\$ 24,522	\$ 342	\$ 516,057
Depreciation	2,492	90,667	56,933	2,862	72	153,027
As at March 31, 2023	9,208	482,047	150,030	27,384	415	669,084
Depreciation	831	30,565	34,491	1,326	24	67,237
As at June 30, 2023	10,039	512,612	184,521	28,711	439	736,321
Depreciation	2,310	272,904	70,983	1,423	61	391,958
As at March 31, 2024	\$ 12,348	\$ 785,516	\$ 255,504	\$ 30,134	\$ 500	\$1,128,279
Net carrying value						
As at June 30, 2023	\$ 14,122	\$ 517,596	\$ 417,668	\$ 5,915	\$ 410	\$ 955,711
As at March 31, 2024	\$ 16,320	\$ 263,748	\$ 501,879	\$ 8,034	\$ 349	\$ 958,846

For the nine months ending March 31, 2024, the Company recognized \$391,958 in depreciation in cost of goods sold in the consolidated statements of net loss and comprehensive loss.

8. Right-of-Use Asset and Lease Liability

	Right-of-Use Asset	Lease Liability
Balance Outstanding, June 30, 2022	\$ 248,730	\$ 316,084
Additions	-	-
Interest	-	22,980
Repayments	-	(114,352)
Adjustments	-	(38,510)
Amortization	(85,043)	7,676
Balance Outstanding, March 31, 2023	163,687	193,876
Additions	-	-
Interest	-	5,777
Repayments	-	(39,359)
Adjustments	-	18,042
Amortization	(28,348)	2,559
Balance Outstanding, June 30, 2023	135,339	180,896
Additions	172,184	172,184
Interest	-	34,869
Repayments	-	(151,333)
Adjustments	-	(15,351)
Amortization	(114,637)	7,676
Balance outstanding, March 31, 2024	192,886	228,940
Allocated as:		
Current	-	67,656
Non-current	192,886	161,284
Total	192,886	228,940

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

Right-of-use assets comprise of production facility lease and are amortized over 60 months.

The lease payments are discounted using an interest rate of between 12% and 15%, which is the Company's incremental borrowing rate. The first lease expired on March 24, 2024 and was renewed. The new lease expiration date is March 31, 2029. The second lease began November 1, 2020 and has an expiry date of October 31, 2025. The third lease began on July 1, 2023 and has an expiry date of June 30, 2028.

9. Intangibles

"Joints" and "Hustle & Shake" brands	
Cost	
As at July 1, 2022	-
Additions in the period	2,750,000
As at March 31, 2023	2,750,000
Additions in the period	-
As at June 30, 2023	2,750,000
Additions in the period	-
As at March 31, 2024	2,750,000
Accumulated Amortization	
As at June 30, 2022	-
Depreciation in the period	(308,904)
As at March 31, 2023	(308,904)
Depreciation in the period	(137,123)
As at June 30, 2023	(446,027)
Depreciation in the period	(412,500)
As at March 31, 2024	(858,527)
Net carrying value	
As at March 31, 2024	1,891,473

10. Trade and Other Payables

Trade and other payables are principally comprised of amounts outstanding for trade purchases on operating activities. The following comprises trade and other payables:

	31/Mar/24	30/Jun/23
Trade Payables	11,812,818	8,283,593
Other Payables	2,396,261	1,142,448
Trade and Other Payables	14,209,080	9,426,041

The standard maturity terms of the Company's trade and other payables are 30 to 60 days.

The following is an aging analysis of the Company's trade and other payables:

	Current	31 to 60	61 to 90	91+	Total
Balance Outstanding, July 1, 2022	\$ 1,084,154	\$ 2,509	\$ 429,318	\$ 92,157	\$ 1,608,139
Change	4,537,126	893,622	434,077	810,629	6,675,454
Balance Outstanding, June 30, 2023	5,621,281	896,131	863,396	902,786	8,283,593
Change	1,078,535	914,606	(783,613)	2,319,698	3,529,225
Balance Outstanding, March 31, 2024	\$ 6,699,815	\$ 1,810,737	\$ 79,782	\$ 3,222,484	\$ 11,812,818

As at March 31, 2024 the Company had \$11,812,818 of Trade A/P (June 30, 2023 - \$8,283,593) of which 72% were outstanding for 60 days and below.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

11. Key Management Compensation

The Company defines key management personnel as its President, Chief Executive Officer and Directors. Key management compensation for the three and nine months ended March 31, 2024 comprised executive fees of \$236,750 and \$596,750 respectively (March 31, 2023 – \$83,500 and \$283,870, respectively), of which \$111,250 and \$278,750 respectively was in the form of share-based payments (see Note 13).

12. Related Party Transactions and Balances

As at March 31, 2024, there were promissory notes of \$400,000 payable to the CEO and the COO (March 31, 2023 - \$400,000) in equal shares. Interest incurred on related party balances payable to the CEO and COO was at \$nil. This interest is included in Trade and Other Payable.

13. Share Capital

a. Authorized Shares

An unlimited number of common shares

b. Issued Shares

For the year ended June 30, 2023:

During the year ended June 31, 2023, 1,226,350 shares were issued at a deemed price of \$0.095 on the vesting of RSUs to certain directors, officers, employees, and consultants of the Company pursuant to the Company's RSU plan. The RSU's vested on grant and were immediately exercised into common shares.

On September 7, 2022 (See Note 4) the Company issued 32,352,941 common shares on closing of the acquisition of Joints and Hustle at a fair value of \$2,750,000.

On October 17, 2022, the Company announced it had settled debt owing to 2388765 Ontario Inc. a company controlled by Igal Sudman, the Chief Executive Officer of the Company ("238") and IIPAC Inc. a company controlled by Roman Buzaker, the Chief Financial Officer of the Company ("IIPAC") in the amount of \$60,000 (the "Transaction"). As part of the Transaction, 238 and IIPAC each converted \$30,000 of their respective debt owed by the Company into 475,435 common shares in the capital of the Company ("Common Shares"), at a deemed price of \$0.0631 per Common Share. In addition, the Company settled debt owing to the Board of Directors in the amount of \$23,750 into 376,384 common shares at a deemed price of \$0.0631 per Common Share.

On January 10, 2023, the Company announced it had settled debt owing to 238 and IIPAC and the directors of the Company by issuing 1,675,000 common shares for the settlement of \$83,750 in debt.

On April 11, 2023, the Company announced it had settled debt owing to 238 and IIPAC and the directors of the Company by issuing 1,675,000 common shares for the settlement of \$83,750 in debt.

During the year ended June 30, 2023, under the Company's normal course issuer bid the Company acquired 464,500 common shares under the share buy-back program at prices between \$0.05 - \$0.11 per common share.

For the nine months ended March 31, 2024:

On July 7, 2023, the Company issued 1,675,000 shares at a deemed price of \$0.05 to certain directors and officers of the Company as non-cash compensation.

On October 2, 2023, the Company issued 1,675,000 shares at a deemed price of \$0.05 to certain directors and officers of the Company as non-cash compensation.

On January 5, 2024, the Company issued 30,240,000 shares to 1000677847 ONTARIO INC and 2388765 ONTARIO INC (15,120,000 shares each) at a deemed price of \$0.047 as non-cash bonus.

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

On January 9, 2024, the Company issued 1,675,000 shares at a deemed price of \$0.05 to certain directors and officers of the Company as non-cash compensation.

On January 15, 2024, the Company issued 550,000 shares at a deemed price of \$0.05 to certain directors and officers of the Company as non-cash compensation.

c. Warrants

A summary of the Company's warrants for the nine months ended March 31, 2024 and March 31, 2023 is presented below:

	Number of Warrants	Average Exercise
Balance Outstanding, June 30, 2022	15,289,504	\$ 0.210
Expired warrants	(5,878,000)	(0.140)
Balance Outstanding, March 31, 2023	9,411,504	\$ 0.160
Balance outstanding, June 30, 2023	9,411,504	\$ 0.160
Balance outstanding, March 31, 2024	9,411,504	\$ 0.160

As at March 31, 2024, the following warrants were outstanding and exercisable:

Date of Grant	Number of Warrants	Exercise Price	Expiry Date
28/Apr/21	1,602,556	\$ 0.38	28/Apr/24
06/Oct/21	7,808,948	0.22	06/Oct/24
	9,411,504		

- (i) On April 28, 2021 the Company issued 1,594,795 warrants and 7,761 broker warrants in connection with a private placement. Each warrant is exercisable into one common share at a price of \$0.38 per share and expires on April 28, 2024. The fair value of \$126,487 was assigned to the warrants and has been estimated using the Black-Scholes model for pricing warrants under the following assumptions: risk free interest rate – 0.48%; dividend yield 0%; expected stock volatility – 100.87% and an expected life of 3 years.
- (ii) Prior to the completion of the reverse take-over transaction, Canada Coal had 5,000,000 warrants outstanding. The majority of the warrants were due to expire prior to effecting the transaction. Canada Coal effected a share consolidation on the basis of 2:1 and there were only 1,087,500 warrants accounted for with an exercise price of \$0.40 and expiry date of January 23, 2022.
- (iii) On October 6, 2021 the Company issued 7,710,354 warrants and 98,594 broker warrants in connection with a private placement. Each warrant is exercisable into one common share at a price of \$0.22 per share and expires on October 6, 2024. The fair value of \$654,262 was assigned to the warrants and has been estimated using the Black-Scholes model for pricing warrants under the following assumptions: risk free interest rate – 1.02%; dividend yield 0%; expected stock volatility – 86.28% and an expected life of 3 years.
- (iv) On October 29, 2021, in connection with the completion of the Build-Out and further to the Company's press release dated November 25, 2020, the Company has provided Health Canada with notice that the Build-Out has been completed, triggering the second and final earn-out entitlement to original Ayurcann Inc. shareholders of an aggregate of 5,159,958 common shares of the Company.
- (v) During the year ended June 30, 2023, 5,878,000 warrants expired unexercised (Year ended June 30, 2022 – 9,628,961)

d. Stock options

The Company has a Share Option Plan (the "Plan") under which it is authorized to grant options to purchase

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

common shares of the Company to directors, senior officers, employees and/or consultants of the Company. The aggregate number of shares of the Company which may be issued and sold under the Plan will not exceed 10% of the total number of common shares issued and outstanding from time to time. Share options are granted with a maximum term of ten years with vesting requirements at the discretion of the Board of Directors.

	Number of Options	Average Exercise
Balance outstanding, June 30, 2022	2,622,068	\$ 0.180
Expired (iii)	(888,688)	\$ 0.260
Balance outstanding, June 30, 2023	1,733,380	\$ 0.200
Expired (iv)	(110,213)	0.101
Balance outstanding, March 31, 2024	1,623,167	\$ 0.194

- (i) On November 24, 2023, 110,213 options of the Company expired unexercised.
- (ii) On April 11, 2022, the Company issued 133,233 options with an expiry date of April 11, 2025, and a strike price of \$0.17.
- (iii) On March 25, 2022, 625,000 options of the Company originally issued on September 22, 2016, expired unexercised.
- (iv) For the year ended June 30, 2023, 888,688 options of the Company expired unexercised.

The following table reflects the stock options issued and outstanding as of March 31, 2024:

Expiry Date	Exercise Price	Options Outstanding	Options Exercisable
13/Apr/24	0.160	1,000,100	1,000,100
11/Apr/25	0.170	133,233	133,233
	\$ 0.161	1,133,333	1,133,333

14. Reclassification

Certain comparative figures have been reclassified to conform to the current year's presentation on the consolidated financial statements and the consolidated statements of loss. Net loss previously reported has not been affected by these reclassifications.

15. Financial Instruments and Risk Factors

(a) Fair value of financial instruments

The fair values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term or demand nature of these balances. The Company's financial instruments are exposed to certain financial risks, as summarized below.

(b) Credit risk

Credit risk arises from trade accounts receivable. The maximum exposure to credit risk as at March 31, 2024 is \$5,044,345 which represents accounts receivable in the consolidated statement of financial position.

The Company's credit risk is attributable to its accounts receivable, which are comprised of trade accounts receivable. The credit quality of the Company's customers is considered high and is monitored on an on-going basis.

(c) Liquidity risk

The business of the Company necessitates the management of liquidity risk. The Company's objective is to mitigate short-term liquidity risk by maintaining adequate working capital reserves and its long-term liquidity risk through

Ayurcann Holdings Corp.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
(Expressed in Canadian Dollars)
For the three and nine months ended March 31, 2024 and 2023

good relations with external capital markets.

The Company is exposed to liquidity risk or the risk of not meeting its financial obligations as they come due. Most of the Company's financial liabilities are due within one year except for finance lease obligations.

The Company manages liquidity risk through the management of its capital structure and resources to ensure that it has sufficient liquidity to settle obligations and liabilities when they are due. Management keeps track of its operational needs and creates budgets and cash flow estimates to determine cash flow requirements for general business and working capital needs, as well as growth projects. The Company's ability to meet its operational needs is dependent on future operating results and cash flows, which are determined by economic, financial, competitive, market, regulatory factors and other factors.

(d) Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates and equity prices.

(i) The Company does not have assets or liabilities in a foreign currency and therefore is not exposed to foreign currency risk.

(ii) Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not subject to interest rate risk from any of its liabilities as the CEBA loan will be a fixed interest when it converts to a term loan.

16. Subsequent events

On April 13, 2024, 1,000,100 options at the exercise price of \$0.16 expired unexercised.

On April 28, 2024, 1,602,556 warrants at the exercise price of \$0.38 expired unexercised.